Benefits of Vasomedical's EECP Therapy Presented at the European Society of Cardiology Congress.

WESTBURY, N.Y. -- Vasomedical, Inc. (Nasdaq SC: VASO), a leader in the non-invasive treatment and management of cardiovascular diseases, today announced that two separate presentations on the clinical improvements achieved with EECP(R) therapy in the treatment of heart disease were presented at the European Society of Cardiology (ESC) Congress held in Munich, Germany.

Angela Brown, M.D., of the Department of Cardiology at Beaumont Hospital in Dublin, Ireland, presented the results of a study entitled, "Diabetic Patients Have a Good Response to EECP Despite Lower Diastolic Augmentation than Non-diabetics." Diabetic patients with coronary artery disease (CAD) are often more difficult to treat and have worse outcomes with invasive cardiovascular procedures than non-diabetic CAD patients. Dr. Brown's analysis of patients from the International EECP Patient Registry (IEPR) demonstrates diabetics with CAD appear to respond less well than non-diabetic CAD patients while undergoing EECP therapy, however, they do obtain a significant reduction in angina symptoms following treatment.

Ozlem Soran, M.D., Assistant Professor at the Cardiovascular Institute at the University of Pittsburgh Medical Center, presented "Comparison of Clinical Outcomes, Rates of Event-free Survival, and Repeat EECP in Women and Men Undergoing EECP for Angina Management." Women with CAD often present with a more complex set of health conditions than men, making them more difficult to treat. Dr. Soran's analysis of patients from the IEPR demonstrates that despite these differences, women respond just as well as men to EECP therapy.

The European Society of Cardiology, founded in 1950, now includes 47 National Societies, 24 Working Groups, two Associations, a Science Council and over 37,000 members. The Annual Congress of the ESC, held this year in Munich from August 28th through September 1st, is the largest medical forum in Europe and presents the latest developments in experimental and clinical cardiology.

About EECP(R) Therapy - Enhanced External Counterpulsation 

Vasomedical's advanced, state-of-the-art EECP(R) external counterpulsation system is comprised of an air compressor, a computer console, a set of cuffs and a treatment table. To receive treatment, patients lie down on the table and have their calves and lower and upper thighs wrapped in the cuffs. The system, which is synchronized to the individual patient's cardiac cycle, inflates the cuffs with air to create external pressure when the heart is resting (diastole) and deflates the cuffs just before the heart beats (systole). The system's action, which pulses counter to the heart's beating, increases blood flow to the heart muscle, decreases the heart's workload and creates a greater oxygen supply for the heart muscle while lowering the heart's need for oxygen.

Treatment is typically given in 35 one-hour-sessions over seven weeks; the benefits have been shown to persist for years. Researchers hypothesize that EECP(R) therapy may work by promoting the release of beneficial growth factors, by improving the neurohormonal milieu within blood vessels and by encouraging the proliferation of collateral blood vessels. Vasomedical's EECP(R) systems are the only counterpulsation devices shown in clinical studies published in major peer-reviewed journals to provide improvements in exercise capacity, peak oxygen consumption and quality of life.

About Vasomedical

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP(R) external counterpulsation systems based on the Company's proprietary technology. EECP(R) therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP(R) equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. EECP(R) is a registered trademark for Vasomedical's enhanced external counterpulsation system. Additional information is available on the Company's website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate", "believes", "estimate", "expect", "should", "intend", "projects", "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.